We are live on
!
Find out more
TCM
Tamarack Capital Management Portfolio holdings
AUM
$840M
1-Year Est. Return
19.47%
This Fund
S&P 500
This Quarter
Est. Return
+22.45%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$659M
AUM Growth
+$208M
(+46%)
Cap. Flow
+$120M
Cap. Flow
% of AUM
18.19%
Top 10 Holdings %
Top 10 Hldgs %
61.19%
Holding
42
New
12
Increased
12
Reduced
11
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$36.6M |
| 2 |
Becton Dickinson
BDX
|
+$16.4M |
| 3 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$15.9M |
| 4 |
DexCom
DXCM
|
+$11.5M |
| 5 |
Perrigo
PRGO
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CFN
CAREFUSION CORPORATION
CFN
|
+$24.2M |
| 2 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
+$19.4M |
| 3 |
MiMedx Group
MDXG
|
+$13.3M |
| 4 |
Alkermes
ALKS
|
+$7.64M |
| 5 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$7.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.41% |
| 2 | Technology | 0.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NTUS
26
DELISTED
Natus Medical Inc
NTUS
| $8.04M | 1.22% |
223,236
-51,459
| -19% | -$1.73M |
|
|
27
MiMedx Group
MDXG
$622M
| $7.5M | 1.14% |
650,000
-1,350,000
| -68% | -$13.3M |
|
|
28
CALL
MiMedx Group
MDXG
$622M
| $6.63M | 1.01% |
+575,300
| New | +$5.68M |
|
|
STRM
29
DELISTED
Streamline Health Solutions
STRM
| $4.93M | 0.75% |
75,867
| – | – |
|
|
IMPR
30
DELISTED
IMPRIVATA, INC COM
IMPR
| $4.91M | 0.75% |
377,924
+77,924
| +26% | +$1.08M |
|
|
CFN
31
DELISTED
CAREFUSION CORPORATION
CFN
| $4.66M | 0.71% |
78,500
-421,500
| -84% | -$24.2M |
|
|
CORI
32
DELISTED
Corium International, Inc.
CORI
| $4.58M | 0.69% |
750,100
+82,521
| +12% | +$469K |
|
33
Bio-Techne
TECH
$11.2B
| $3.7M | 0.56% |
+160,000
| New | +$3.66M |
|
34
PUT
Boston Scientific
BSX
$72B
| $3.64M | 0.55% |
+275,000
| New | +$3.52M |
|
|
TRIB
35
Trinity Biotech
TRIB
$7.51M
| $2.19M | 0.33% |
+833
| New | +$2.15M |
|
|
WINT
36
DELISTED
Windtree Therapeutics Inc
WINT
| $1.74M | 0.26% |
107,143
| – | – |
|
37
ICU Medical
ICUI
$4.32B
| $1.14M | 0.17% |
13,875
-66,250
| -83% | -$5.08M |
|
38
Standard BioTools
LAB
$339M
| $824K | 0.13% |
+24,442
| New | +$692K |
|
|
XENT
39
DELISTED
Intersect ENT, Inc
XENT
| $337K | 0.05% |
+18,149
| New | +$327K |
|
|
VOLC
40
DELISTED
VOLCANO CORPORATION COM STK
VOLC
| – | – |
-500,000
| Closed | -$5.32M |
|
|
AUXL
41
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| – | – |
-650,000
| Closed | -$19.4M |
|
|
CBST
42
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| – | – |
-110,000
| Closed | -$7.3M |
|
Similar funds
RI
CWA
GHF
F
TRV
BMCMI
GACM
AH
Tamarack Capital Management's Q4 2014 Portfolio in Review
As of Q4 2014, Tamarack Capital Management held 42 positions worth $659M, up 46% from $451M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Tamarack Capital Management deployed $120M of net new capital in Q4 2014, opening 12 new positions and adding to 12 existing holdings. Its largest new stake was Quest Diagnostics: 580,000 shares worth $38.9M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 56% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was CAREFUSION CORPORATION, an estimated $24.2M trimmed.
- Tamarack Capital Management's largest Q4 2014 buy was Quest Diagnostics: 580,000 shares worth $38.9M.
- Tamarack Capital Management added most to Becton Dickinson in Q4 2014, an estimated $16.4M increase.
- Tamarack Capital Management's biggest Q4 2014 reduction was CAREFUSION CORPORATION, cutting an estimated $24.2M.
- Tamarack Capital Management fully exited AUXILIUM PHARAMCEUTICALS INC in Q4 2014, selling an estimated $19.4M.
- Tamarack Capital Management's ten largest holdings make up 61% of its $659M portfolio in Q4 2014.
- Tamarack Capital Management opened 12 new positions and closed 3 in Q4 2014.
- Tamarack Capital Management's portfolio value rose 46% quarter-over-quarter to $659M.
Based on Tamarack Capital Management's 13F filing for Q4 2014, filed 11 Feb 2015.